实验研究强调植物来源的光敏剂在光动力疗法中的治疗潜力。此外，多个体外和体内研究表明，一些不太知名的蒽醌类物质具有选择性地靶向癌细胞，并在光照射后消除它们的有希望的作用。本文综述了目前关于选择的植物光敏剂在光动力疗法中的作用的研究成果，阐述了侧柏素、芦荟侧柏素、鸟过江瑟雨等多种植物光敏剂在癌症治疗中的光动力疗法中的应用结果，并描述了它们作为天然光敏剂的综合视角。通过在PubMed.gov进行关键词为"emodin"、"aloe-emodin"、"hypericin"、"parietin"、"rubiadin"、"soranjidiol"的蒽醌类物质与"癌症"和"光动力疗法"的文献搜索，对所选择的蒽醌类物质进行了系统的文献综述。根据文献数据，本综述聚焦于侧柏素、芦荟侧柏素、新大黄素、鸟过江瑟雨在抗癌治疗中作为天然光敏剂的所有现有体内外研究，强调它们的有效性和详细的作用机制。此外，全面的临床前和临床研究证实，对于hypericin，上述物质可能被纳入不同癌症的光毒性治疗中。总的来说，本综述介绍了不太知名的蒽醌类物质及其有希望的分子作用机制。预计未来它们可能作为天然的光敏剂在癌症治疗以及hypericin中得到应用。Copyright © 2023. Elsevier GmbH出版。

Experimental studies emphasize the therapeutic potential of plant-derived photosensitizers used in photodynamic therapy. Moreover, several in vitro and in vivo research present the promising roles of less-known anthraquinones that can selectively target cancer cells and eliminate them after light irradiation. This literature review summarizes the current knowledge of chosen plant-based-photosensitizers in PDT to show the results of emodin, aloe-emodin, parietin, rubiadin, hypericin, and soranjidiol in photodynamic therapy of cancer treatment and describe the comprehensive perspective of their role as natural photosensitizers.Literature searches of chosen anthraquinones were conducted on PubMed.gov with keywords: "emodin", "aloe-emodin", "hypericin", "parietin", "rubiadin", "soranjidiol" with "cancer" and "photodynamic therapy".According to literature data, this review concentrated on all existing in vitro and in vivo studies of emodin, aloe-emodin, parietin, rubiadin, soranjidiol used as natural photosensitizers emphasizing their effectiveness and detailed mechanism of action in anticancer therapy. Moreover, comprehensive preclinical and clinical studies on hypericin reveal that the above-described substances may be included in the phototoxic treatment of different cancers.Overall, this review presented less-known anthraquinones with their promising molecular mechanisms of action. It is expected that in the future they may be used as natural PSs in cancer treatment as well as hypericin.Copyright © 2023. Published by Elsevier GmbH.